Intellia Therapeutics (NTLA) PT Raised to $99 at Brookline Capital Markets
Tweet Send to a Friend
Brookline Capital Markets analyst Leah RUsh Cann raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $99.00 (from $71.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
